Browse Tag

biopharmaceutical company

Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate

3 mins read

The FINANCIAL — Medicago, a biopharmaceutical company headquartered in Quebec City, and GSK are pleased to announce the start of Phase 2/3 clinical trials of its plant-derived vaccine candidate for COVID-19 to evaluate its efficacy, safety, and immunogenicity.  Based on the positive Phase 1 results, Medicago has decided to launch the Phase 2/3 clinical trial with GSK’s pandemic adjuvant. Nathalie Landry, Executive Vice President, Scientific and Medical Affairs at Medicago, said: “Our Phase 1 results of the adjuvanted vaccine candidate were very encouraging and fully support further clinical evaluation.” Thomas Breuer, Chief Medical Officer GSK Vaccines said: “This is the first…

Read More »

Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate

3 mins read

The FINANCIAL — Medicago, a biopharmaceutical company headquartered in Quebec City, and GSK are pleased to announce the start of Phase 2/3 clinical trials of its plant-derived vaccine candidate for COVID-19 to evaluate its efficacy, safety, and immunogenicity.  Based on the positive Phase 1 results, Medicago has decided to launch the Phase 2/3 clinical trial…

Bayer acquires AskBio for $4 bln

6 mins read

The FINANCIAL — Bayer AG today announced the acquisition of Asklepios BioPharmaceutical, Inc. (AskBio), a US-headquartered biopharmaceutical company specialized in the research, development and manufacturing of gene therapies across different therapeutic areas. AskBio’s development portfolio includes investigational pre-clinical and clinical stage candidates for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic diseases. Bayer…

PMI announced Medicago to supply up to 76 mln doses of its plant-derived coronavirus vaccine candidate

4 mins read

The FINANCIAL — Since 2008, Philip Morris Investments B.V. (PMIBV), a subsidiary of Philip Morris International (PMI) (NYSE: PM), has been a shareholder of Medicago (in which it currently holds an approximately one-third equity stake) and has supported Medicago’s innovative plant-derived research and development focused on vaccines. The investment is consistent with PMI’s own efforts to leverage science…